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A B S T R A C T
In renal cancer emerging treatment options are becoming available and there is a strong need to combine
therapies to reformulate and adjourn clinical practice. We here highlight and discuss the need to take advantage
of the common immune targets to design combined strategies to increase clinical responses.
Personal view
The introduction of immune checkpoint inhibitors (ICIs) in clinical
practice has revolutionized the scenario and the outcome of cure in
oncology. The immune system is a complex network where the several
mechanisms and interactions involved are continuously discovered.
More than ever translational scientists are close to the clinicians to
better understand patients immune response to cancer in order to po-
tentiate possible avenues of cure. Several if not all standard therapies
that represent today the gold standard in oncology need to be char-
acterized from an immunological point of view for a necessary in-
tegration process that must be done to optimize protocols of cure.
From this point of view we want to discuss and share some of the
critical points in the clinical management of anti angiogenic drugs,
particularly Tyrosine Kinase Inhibitors (TKIs) and immunotherapy.
TKIs are important drugs that target receptors involved in the
neoangiogenesis of tumors, such as the Vascular Endothelial Growth
factor (VEGF) pathway, and they have contributed to changing life
expectancy particularly of renal cancer patients [1,2]. In renal cancer,
the activation of genes of the hypoxic response results in the down-
stream activation of pro-angiogenic growth factors like VEGF. Together
with sunitinib, sorafenib, pazopanib, axitinib, most recently drugs tar-
geting possible pro-angiogenic resistance mechanisms, lenvatinib and
cabozantinib are also available.
The increase in treatment options including ICI has added com-
plexity to clinical questions on how to choose first-line treatment and
treatments after recurrence [2].
Tumor associated angiogenesis and immune system
Tumor progression is characterized by a number of mutational
events that confer to the initially transformed cells a number of dis-
tinctive and functional features associated with invasive potential and
expression of tumor associated antigens. A class of these, the neoanti-
gens are not essential for tumor progression, but are important in
generating an immune response in the patient. Indeed the presence of a
relevant anti-tumor immune infiltrate is associated with an increased
mutational tumor burden; moreover these tumors have been shown to
respond better to ICI [3,4]. Despite immune activation, tumors are able
to evade immunological control and after a phase of equilibrium that
can also be prolonged in time, they finally enter in the escape phase
characterized by several immunosuppressive traits and independence
from any kind of immune control.
In this scenario the tumor microenvironment appears to have an
important role and a number of studies are now focalizing in under-
standing the dynamics of these interactions during tumor progression.
The growing tumor establishes from the beginning a complex net-
work of cross-talk between tissue resident stromal cells and immune
cells, which are also resident but more frequently recruited ad hoc from
the bone marrow and circulation. Tumor directed vascularization or
tumor angiogenesis appears to involve several molecules, cells and
signaling pathways. One of the main leaders in this crucial step, the
angiogenic switch, which allows the tumor to acquire the invasive be-
haviour and a fully metastatic potential is the VEGF. Hypoxic cancer
cells are able to secrete VEGF which engages the specific receptor on
the endothelial cells that in turn proliferate, gradient guided to generate
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new blood vessel sprouts characterized by impaired vascular matura-
tion, poor functionality and defects in endothelial architecture [5]. The
immaturity of the new generated tumor associated vasculature results
in excessive permeability, poor perfusion and imperfect blood flow.
This has direct impact on anticancer treatment efficacy [6].
Moreover angiogenesis has an important influence on the immune
system and these processes appear to be intimately linked. The vascular
network with its specific components, endothelial cells, pericytes,
growth factors and receptors is fundamental in the inflammatory re-
sponse, in wound healing and in immune surveillance [7]. T cells,
particularly antigen primed T cells, need a healthy endotelium for the
trafficking to tissue districts and the cell to cell cross-talk that is es-
tablished during the priming and effector phase of the immune re-
sponse.
This is the basic principle of immune surveillance that relies on an
efficient vascular-lymphatic circulation and endothelia that can be
viewed as “critical non-hematopoietic components of the immune
system” [8].
The access of immune cells into the tumor becomes a critical issue
for the outcome of immunotherapeutic strategies such as adoptive cell
transfer and expansion of tumor specific T cells with ICIs. Moreover also
classical chemotherapeutic drugs have been shown to benefit for op-
timal efficacy of an intact immune system thus suggesting a synergy
between cancer cell death and immune activation [9]. A normalized
endothelium is preferred assuring the correct trafficking of T cells to the
tumor bed since it is now well established that the presence of tumor
infiltrating lymphocytes correlates with improved prognosis for most
tumors [10]. The process of T cell infiltration is regulated by several
variables. The type of T cell repertoire that can be described in the
tumor depends on tumor released factors, on the cytokine/chemokine
secreted and relies during the tumor growth, on the first encounter
between the initial transformed cells and resident antigen presenting
cells. Dendritic cells (DCs) as first sentinel cells are empowered to de-
liver the correct Th1 signalling to generate tumor specific T cells by
endocytating dead neoplastic cells or cellular debris, transporting
tumor antigen to the draining lymph nodes and cross-presenting anti-
gens to T cells. Expression of an array of receptors and molecules on the
surface of DCs is required to deliver the correct non tolerogenic sig-
naling (DC maturation) [11]. Activated T cells can now expand and
home to the tumor to exert the effector functions. This whole process,
theoretically simple and smooth, is tightly regulated and can be per-
turbed by a number of factors and variables. These include all the well
described immune tumor evasion mechanisms such as phenotypic
changes in DCs induced for example by VEGF, PGE2, IL-10, tumor
hypoxia. The T cell tumor infiltrate can also be populated by a variety
of immunosuppressive cells usually attracted by the tumor and with the
ability to counteract immune anti tumor activity: Regulatory T cells
(Tregs), Myeloid Derived Suppressor cells (MDSCs) and Tumor asso-
ciated macrophages (TAMs) [12]. So in the end the balance between
immune activation and immune suppression will determine or at least
influence significantly the outcome of any cancer treatment that relies
or utilizes immunity networks.
The distinction between “hot” and “cold” tumors is relatively new.
Some tumors have been defined as naturally “hot” such as melanoma
characterized by a high mutational load in cancer cells associated with
neoepitope expression and induction of tumor specific T cells [13–15].
For these tumors the possibility that ICI immunotherapy would work is
relatively high since it is believed that the tumor microenvironment
already has a repertoire of exhausted PD-1+ T cells ready to be ex-
panded. Responder patients are probably these, in which the immune-
balance was in equilibrium and activation just needed to be unleashed
to take over. A “cold” tumor has little or no T cell infiltration like
prostate cancer, and therefore the efficacy of an ICI treatment can be
null or very limited. Cold tumors are also those where a T cell in-
filtration can be observed but is localized in the periphery of the tumor
suggesting a sort of limited access probably due to the tumor stroma
including the vasculature network [16,17].
Tumor associated angiogenesis and anti cancer therapies
The efficacy of most of the anti cancer therapies is severely impaired
by the imperfect newly generated blood vasculature. The interruption
of a regulated blood flow will not allow sufficient drug delivery in the
tumor particularly in all the different areas. Therefore efficacy of the
treatment will be compromised. It should be emphasized that this effect
is highly variable among patients and between tumors and can explain
why patients respond only initially to treatment. The other important
finding is that we know today that anti-angiogenic drugs can reduce
dramatically cancer induced immunosuppression, simply because the
targets such as VEGF and its receptors are the main actors in this pro-
cess.
The initial idea that led to the generation of anti-angiogenesis drugs
was to operate a pruning effect of the tumor associated blood vessels to
induce tumor starvation. The dosing and schedule of antiangiogenic
drugs has been revolutionized by Jain’s hypothesis demonstrated in
animal models that the “judicious” use of antiangiogenic agents could
transiently normalize tumor vasculature, diminish hypoxia, reduce
immunosuppression and improve efficacy of different therapies [18].
This hypothesis puts the basis for using anti angiogenic therapies and
immunotherapies in combination more than as single agents. Clinical
data confirm and sustain the validity of this thesis i.e chemotherapy and
immune therapy require functional blood vessel for optimal efficacy
[19]. The recent outstanding results from the combinations of ICI and
chemotherapy in lung cancer strengthens furthermore this rationale
and encourages the design of novel combination and /or sequential
clinical trials using drugs targeting different mechanisms (tumor cell
death, endothelium, immunity).
In the last few years we have also learned that chemotherapy can
influence immunity and is able to target and normalize cancer en-
dothelium, when given in a metronomic fashion [8]. The real in-
novative and relevant application of metronomic chemotherapy is the
combination with immunotherapy by directly affecting the im-
munosuppressive tumor microenvironment. Cyclophosphamide, with
its well known effect in depleting the Treg population, is one of the
most used drugs in a variety of cancer vaccine protocols as a tool to
make space for the newly activated specific T effector cells, which
would be liberated by the immunosuppressive milieu [20].
Targeting angiogenesis and the immune system: Learning from
patients’ immune system
Endothelium is recognized as a major contributor in the efficacy of
the immune response and several receptors are shared between parti-
cipant cells. Research efforts have been directed in understanding the
immune effects of anti angiogenic drugs. The interest is becoming ur-
gent since with the possibility to introduce the ICIs during or combined
with the anti angiogenic treatments in several cancers it is mandatory to
consider these drugs from the point of view of their impact on the pa-
tient’s immune system. The important question is: can we use the
normalization effect induced by the anti angiogenic drugs to potentiate
immunotherapeutic strategies? Moreover how are the shared receptors
among immune cells, i.e. VEGFR, influenced by the therapy? Can we
use anti-angiogenetic drugs to turn a “cold” tumor into a “hot” one and
prepare the cancer patient for a successful ICI therapy?
The best readouts are of course the patients. Each of them has its
own immune system, which has been shaped during life starting from
host genetic factors and modulated in time by history of infectious
diseases, environmental and lifestyle factors, stress and microbioma
repertoire [21]. When the patient arrives to our attention with a di-
agnosed cancer, we need to consider not only the nature (histotype,
genomic portrait, etc.) of the malignancy but also the immunological
“fitness” of the patient, particularly at the tumor level. This is a novel
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approach and the new immunotherapy drugs require this information.
In our laboratory we have performed longitudinal studies on pher-
ipheral blood of cancer patients undergoing anti-angiogenetic and/or
chemo-immuno therapies. Recently, we reported results on the im-
munological effect of the TKI pazopanib, a kinase inhibitor targeting
mainly the VEGF-R molecule [22].
Preclinical experiments on monocyte derived DCs indicated that
plasmatic concentration of pazopanib were able to improve DC differ-
entiation and performance, by upregulating maturation markers,
dowregulating co-inhibitors molecules such as PD-L1 and increasing
allogenic response and Th1 cytokine production. We demonstrated that
the shut down of β-catenin pathway was the mechanism involved. The
activation of the β-catenin pathway has been shown to correlate with
the absence of T cells from the microenvironment in metastatic mela-
noma and urothelial cancers. The targeting of the β-catenin pathway
has therefore been suggested as an optimal strategy to reestablish
lymphocyte trafficking within the tumor [23].
A strong DC immunopriming treatment could release from the tol-
erogenic state DCs in the tumor microenvironment and impact the
functionality of effector T cells, presumably tumor specific T cells. We
investigate changes occurring in the immune T cell repertoire of mRCC
during TKI treatment with the intention to capture changes occurring in
the pheripheral blood as a consequence of the treatment. Among the
different biomarkers tested, we were able to detect a CD137+ T cell
subset in mRCC arising during pazopanib treatment. The impact of
these findings needs to be confirmed and validated in an appropriately
designed study, which is currently ongoing. However, we can speculate
that differences in the T cell CD137+ repertoire in cancer patients could
be linked to the rescued potency of DC due to pazopanib treatment and
the appearance of exhausted T cell recirculating in the pheripheral
blood [24].
If this observation is confirmed in larger studies we could propose to
follow with a specific therapy targeting CD137 to expand the anti tumor
T cell population that was mobilized by the TKI treatment.
In our study we did not see similar effect on DC with sunitinib, the
other TKI similarly used in mRCC with identical clinical efficacy. Two
patients treated with Sunitinib however showed upregulation of CTLA4
on pheripheral T cells after one and two months of treatment.
Immunosuppression appears to be downregulated in mRCC patients
treated with sunitinib or axitinib, whose Treg and MSDC cell popula-
tions are affected. Sorafenib has the opposite effect by reducing an-
tigen-specific T-cell induction in vitro [25–30].
An Identical clinical outcome using the two TKI is then justified
although results from CheckMate 025 which was not powered to test
the difference suggest that Pazopanib immunoactivating treatment in
first line in mRCC allows the following ICI treatment to have improved
overall survival [31].
The other consideration that can be made is the timing of the im-
munological effect. We found that immunological changes could be
detected quite early in the pheripheral blood of the patients. This
suggests that the impact on the immunological repertoire is an early
event and this could simplify the immune monitoring analysis since we
would be able to have quite quickly a possible marker of overall re-
sponse. In other words, the rapid changes in the immunological setting
of a patient indergoing ICI therapy could anticipate the direction and
outcome of the immuno treatment.
Immune monitoring technology is continuously improving, adding
novel potential biomarkers that need to be validated in larger studies. It
is however quite clear that it will be extremely difficult to rely on single
“universal” biomarker and that longitudinal studies and im-
munomonitoring of each patient can be of valuable help specially in the
early discovery of novel immune indicators [32]. The longitudinal
evaluation of the immune-tumor status of the patient appears to be
particularly significant since tumor undergoes progression and im-
muno-editing as well as immunosuppression. Therefore a static picture
of the tumor and its microenvironment is totally unrepresentative.
Table 1
Main ongoing trials in renal cancer with combination strategies: immunotherapy, TKI and anti-angiogenic targeted therapy
Trial Phase NCT# Status
A Study of Atezolizumab Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell
Carcinoma [IMmotion151]
III 02420821 Active, not recruiting
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma I/II 03024437 Recruiting
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma II 02724878 Recruiting
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in
Participants With Solid Tumors
I 02715531 Recruiting
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination
WithBevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma
II 01984242 Active, not recruiting
Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants
WithUnresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
I 03063762 Recruiting
Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC) I 02210117 Active, not recruiting
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal
Cell Carcinoma (RCC) (CheckMate 016)
I 01472081 Active, not recruiting
A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer II 02960906 Recruiting
Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine
Kinase Inhibitor in Patients With MetastaticRenal Cell Carcinoma (RCC) and Disease Control
II 02959554 Recruiting
A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients II 02599779 Recruiting
Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018) I/II 02014636 Active, not recruiting
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy
in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
III 02853331 Active, not recruiting
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100) I 02493751 Active, not recruiting
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) III 02684006 Active, not recruiting
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC II 03341845 Recruiting
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
(CLEAR)
III 02811861 Recruiting
CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers I 03454451 Recruiting
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid
Tumors
I 02646748 Recuiting
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor I 03239145 Recruiting
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Selected Solid Tumors I 03006887 Active, not recruiting
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/
Metastatic Solid Tumors
I/II 02903914 Recruiting
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Immunotherapy as “first choice”: Is it always the best choice? The
paradigmatic example of mRCC
Several studies are now being conducted to assess efficacy of com-
bined immuno and target therapies. These will probably result in novel
insights that could help to answer several clinical issues (Table 1).
Recently first line treatment in untreated intermediate and poor-risk
renal-cell carcinoma patients with Ipilimumab and Nivolumab has
shown significantly higher overall survival and objective responses as
compared to treatment with the TKI inhibitor Sunitinib [33]. The
question here is: can clinical parameters drive the choice of im-
munotherapy? Or should we consider more the immunological char-
acteristics of tumors and patients?
Interestingly, a better response with ICI treatment was not observed
in the favorable-risk patients. This is most probably to be ascribed as
discussed in the editorial accompanying the paper by Motzer to the
amount of mutational load that could be increased in high risk patients
[4].
Furthermore, the results of the IMmotion 151 phase II trial de-
monstrated an increased PFS in the combination arm Bevacizumab plus
Atezolizumab as compared with the monotherapy both with
Atezolizumab and Sunitinib [34].
In particular, the PFS of the Bevacizumab plus Atezolizumab arm is
11.2 months (HR was 0.83) the same PFS of the combination arm of
Ipilimumab plus Nivolumab (11.6months and HR 0.82) In spite of the
limitation of a comparison between a phase II and phase III trials these
data could lead to considering the combination therapy as the best
strategy for this category of patients, also with regards to the safety
profile.
The real today challenge of oncology is to determine on the one
hand what will be the best association (combo-immuno vs immuno plus
target therapy) and on the other hand what is the right patient for the
right combination. We must take into consideration that the efficacy of
immunotherapy depends strictly on the immunological history of
tumor/microenvironment interaction and on the immune system of the
patients.
Furthermore, these “two sides of the same coin” are extremely dy-
namic so we should consider not only the right patient but also the right
moment for a right therapy.
The only way to understand and define personalized im-
munotherapy is to explore the role of the tumor microenvironment, the
lymphocyte trafficking as well as the different cells involved in immune
priming. This needs to be done in pilot studies focalizing on the un-
derstanding of the biological mechanisms involved in the response.
New points of view: The challenge of oncologists
As has happened in the past as new emerging treatment options
become available the most challenging task in medicine is to combine
the new therapies with the standard ones and create, design and ad-
journ new clinical practice.
The intuition and research contribution on ICI of Jim Allison and his
group has changed the life of several patients and has given researchers,
immunologists and oncologists important drugs that have the capability
to unleash tumor specific T cells [35]. The question is now how to in-
crease the number of responder patients, understand the immunity
underlying the non-responder patients, introduce the immunotherapy
drug at the right moment in the cancer therapy protocols, and adjust
doses and combinations to limit toxicities. The other complication is the
number of immunotherapeutic drugs coming onto the market that will
need to be validated, compared to other similar drugs, inserted in dif-
ferent protocols and registered for specific tumors. New clinical trials
often are launched without really looking at possible combined im-
munological toxicities or without solid biological knowledge apparently
just for the sake of combination, i.e. more is better than one [36]. In
fact, in the plethora of recently finished or ongoing clinical trials very
few have given significant insights that will change clinical practice.
In renal cancer it is now quite clear that this tumor is very hetero-
geneous and the heterogeneity has become evident using ICI treatment
in the first clinical trials. For this reason, studies on the impact of the
different drugs on the immune cells and immune monitoring of patients
during treatment can give relevant insights in which setting we can
achieve the best response using the right combination [10].
The best example of the critical issues raised by the several im-
munotherapy targeted therapies waiting for registration, and in the
process of proving efficacy in the clinic, is the possibility to have ne-
gative results from phase II/III clinical trials, This is primarily because
these drugs were combined using an obsolete rationale that was used
for chemotherapy and were not optimally designed with an im-
munologic rationale. The worst implication is that important drugs will
never go to the clinic because we simply did not test them in the right
setting (i.e. with patients immunologically prepared to receive the
drug) [37].
We all agree that we need biomarkers, particularly the predictive
one’s. Biomarkers of response, of toxicity, of resistance. The literature is
overloaded with reports suggesting possible biomarkers. Research in
this field must be enforced and algorithms designed. Most probably we
will have to work with several biomarkers that can design the immune
fitness of the patient rather than a single biomarker. PD-L1 is one of the
most discussed biomarkers which was initially proposed and en-
couraged by pharma for the registrative studies but has failed to show
its reliability. PD-L1 should be regarded as a sign of the degree of im-
munoevasion present in the tumor/immune microenvironment and
probably it would be more appropriate to define it as a prognostic
biomarker. The story of the PD-L1 biomarker clearly shows what im-
munologists know very well: the immune system is easily modulated, is
characterized by redundancy and by the presence of pleiotropic activity
on different cells.
The only way we can successfully proceed in this complicated sce-
nario is to perform studies in strict collaboration with academic in-
stitutions, in close interaction with the laboratory, where there are
strong scientific interests in defining mechanisms and with minimum
conflicts of interests.
We need to carry out immune monitoring guided trials, at least for
small sets of homogeneous patients, where both the immunological and
the tumor responses as well as toxicities, have to be taken into account
for clinical decision making. Methods and technology to assess the
immune fitness of cancer patients need to be implemented and vali-
dated following the patients’ immune responses during the different
treatments (Fig. 1) [38–41]. This could allow for a more defined and
personalized approach including from an immunological point of view
given the possibility of understanding the mechanisms of efficacy or
failure of a given treatment.
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